Page 138 - 南京医科大学自然版

第46卷第5期
·760 · 南 京 医 科 大 学 学 报 2026年5月

treating tyrosine kinase inhibitor ⁃ failed leptomeningeal clinical trial of intrathecal topotecan in patients with neo⁃
metastases from EGFR ⁃ mutant NSCLC ⁃ a prospective， plastic meningitis［J］. J Clin Oncol，2003，21（1）：143-147

open ⁃ label，single ⁃ arm phase 1/2 clinical trial（unique ［48］GROVES M D，GLANTZ M J，CHAMBERLAIN M C，et
identifier：ChiCTR1800016615）［J］. J Thorac Oncol， al. A multicenter phase Ⅱ trial of intrathecal topotecan in
2021，16（8）：1359-1368 patients with meningeal malignancies［J］. Neuro Oncol，
［37］CHEN Y M，CHEN M C，TSAI C M，et al. Intrathecal gem⁃ 2008，10（2）：208-215
citabine chemotherapy for non⁃small cell lung cancer pa⁃ ［49］YAMADA A，KINOSHITA M，KAMIMURA S，et al. Novel
tients with meningeal carcinomatosis ⁃ a case report［J］. strategy involving high⁃dose chemotherapy with stem cell
Lung Cancer，2003，40（1）：99-101 rescue followed by intrathecal topotecan maintenance
［38］BERNARDI R J，BOMGAARS L，FOX E，et al. Phase Ⅰ therapy without whole⁃brain irradiation for atypical tera⁃
clinical trial of intrathecal gemcitabine in patients with toid/rhabdoid tumors［J］. Pediatr Hematol Oncol，2023，40
neoplastic meningitis［J］. Cancer Chemother Pharmacol， （7）：629-642
2008，62（2）：355-361 ［50］STEMMLER H J，SCHMITT M，WILLEMS A，et al. Ratio
［39］KIYA K，UOZUMI T，OGASAWARA H，et al. Penetra⁃ of trastuzumab levels in serum and cerebrospinal fluid is
tion of etoposide into human malignant brain tumors after altered in HER2 ⁃ positive breast cancer patients with
intravenous and oral administration［J］. Cancer Chemother brain metastases and impairment of blood⁃brain barrier［J］.
Pharmacol，1992，29（5）：339-342 Anticancer Drugs，2007，18（1）：23-28
［40］HENWOOD J M，BROGDEN R N. Etoposide. A review of ［51］BOSKOVITZ A，MCLENDON R E，OKAMURA T，et al.
its pharmacodynamic and pharmacokinetic properties， Treatment of HER2⁃positive breast carcinomatous menin⁃
and therapeutic potential in combination chemotherapy of gitis with intrathecal administration of alpha ⁃ particle ⁃
cancer［J］. Drugs，1990，39（3）：438-490 emitting（211）At⁃labeled trastuzumab［J］. Nucl Med Biol，
［41］VAN DER GAAST A，SONNEVELD P，MANS D R，et al. 2009，36（6）：659-669
Intrathecal administration of etoposide in the treatment of ［52］FIGURA N B，RIZK V T，MOHAMMADI H，et al. Clini⁃
malignant meningitis：feasibility and pharmacokinetic cal outcomes of breast leptomeningeal disease treated
data［J］. Cancer Chemother Pharmacol，1992，29（4）： with intrathecal trastuzumab，intrathecal chemotherapy，
335-337 or whole brain radiation therapy［J］. Breast Cancer Res
［42］FLEISCHHACK G，REIF S，HASAN C，et al. Feasibility Treat，2019，175（3）：781-788
of intraventricular administration of etoposide in patients ［53］BONNEAU C，PAINTAUD G，TRÉDAN O，et al. Phase
with metastatic brain tumours［J］. Br J Cancer，2001，84 Ⅰ feasibility study for intrathecal administration of trastu⁃
（11）：1453-1459 zumab in patients with HER2 positive breast carcinoma⁃
［43］SLAVC I，SCHULLER E，FALGER J，et al. Feasibility of tous meningitis［J］. Eur J Cancer，2018，95：75-84
long ⁃ term intraventricular therapy with mafosfamide（n= ［54］OBERKAMPF F，GUTIERREZ M，TRABELSI GRATI O，
26）and etoposide（n=11）：experience in 26 children with et al. Phase Ⅱ study of intrathecal administration of
disseminated malignant brain tumors［J］. J Neurooncol， trastuzumab in patients with HER2⁃positive breast cancer
2003，64（3）：239-247 with leptomeningeal metastasis［J］. Neuro Oncol，2023，25
［44］CHAMBERLAIN M C，TSAO ⁃ WEI D D，GROSHEN S. （2）：365-374
Phase Ⅱ trial of intracerebrospinal fluid etoposide in the ［55］KUMTHEKAR P U，AVRAM M J，LASSMAN A B，et al.
treatment of neoplastic meningitis［J］. Cancer，2006，106 A phase Ⅰ/Ⅱ study of intrathecal trastuzumab in human
（9）：2021-2027 epidermal growth factor receptor 2⁃positive（HER2⁃posi⁃
［45］PARK M J. Prolonged response of meningeal carcinomato⁃ tive）cancer with leptomeningeal metastases：safety，effica⁃
sis from non⁃small cell lung cancer to salvage intrathecal cy，and cerebrospinal fluid pharmacokinetics［J］. Neuro
etoposide subsequent to failure of first⁃line methotrexate： Oncol，2023，25（3）：557-565
a case report and literature review［J］. Am J Case Rep， ［56］AHMED K A，KUMTHEKAR P U，PINA Y，et al. Radia⁃
2015，16：224-227 tion therapy followed by intrathecal trastuzumab ⁃ pertu⁃
［46］PAJTLER K W，TIPPELT S，SIEGLER N，et al. Intraven⁃ zumab for ERBB2⁃positive breast leptomeningeal disease：
tricular etoposide safety and toxicity profile in children a phase 1 nonrandomized controlled trial［J］. JAMA Oncol，
and young adults with refractory or recurrent malignant 2024，10（7）：984-986
brain tumors［J］. J Neurooncol，2016，128（3）：463-471 ［57］JU Y F，WANG J L，SUN S J，et al. Nimotuzumab treat⁃
［47］BLANEY S M，HEIDEMAN R，BERG S，et al. Phase Ⅰ ment and outcome analysis in patients with leptomeningeal